Among head and neck cancers (HNC), the majority, ≤90%, comprise of mutations originating in the squamous epithelium of the upper aerodigestive tract (1). Head and neck squamous cell carcinoma (HNSCC) is the seventh most frequently occurring and the ninth most fatal cancer (1). Standard therapies used for treatment of HNSCC have achieved a consistent five-year survival rate ranging from 40–50% in the past three decades (2). Treatment for the early stage of this disease is a single therapeutic method, including surgery or radiotherapy (2,3). Cure rates of >90 and 70% have been achieved for stage I and II, respectively (3,4). The radical treatment of patients with locally advanced cancer in stage III or IV requires multimodality therapy. At these stages, a surgical treatment is complemented with radiotherapy or chemoradiotherapy, depending on the risk factors for a relapse including: Dubious margin of healthy tissue; poorly differentiated (G3) cancer; and feature pT4 (advanced local disease) or metastases in the regional lymph nodes (5,6). In stage III and IV it is also possible to apply an organ conserving therapy, such as chemo-radiotherapy or targeted therapy using monoclonal antibodies in combination with radiotherapy (6,7); however, the treatment effects are not as satisfactory, compared with the early stages of the disease. Tumor recurrence within two years was ~0% in patients who were treated for a locally advanced HNC (8). In these cases, the possibility of treatment with salvage surgery or re-irradiation is limited (8). The use of chemotherapy in patients with recurrent or metastatic changes results in response rates ranging from 10–35% and a median survival of 6–12 months (9). Concurrent radiochemotherapy in the treatment of HNSCC is complicated due to the occurrence of side effects, including mucositis, dermatitits and dysphagia. The treatment is frequently accompanied by leukopenia and thrombocytopenia, which increases the risk of infection or bleeding (4). Following the treatment, the quality of life deteriorated due to late complications including: Sensorineural hearing loss; polyneuropathy caused by chemotherapy or permanent xerostomia; and impaired swallowing (4). Unsatisfactory outcomes of the HNC treatment using standard methods with high toxicity warrant a search for novel therapeutic options. The search for novel therapies is justified by achievements of genetics and molecular biology, which have initiated the development of targeted cancer therapies (10). These treatments have already been successfully used in the treatment of other solid tumor types, including colorectal or lung cancer (10). The action of targeted drugs consist of inactivating specific target molecules required for oncogenesis and tumor growth (11).

In the present review, a description of the currently most promising and well-known molecular targeting strategies used in the treatment of advanced head and neck cancers were produced. These treatments target (Table I): i) Epidermal growth factor receptor (EGFR), ErbB1; ii) vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR); iii) intracellular signaling pathway components associated with the phosphatidylinositol 3-kinase (PI3K)/serine/threonine-specific protein kinase (AKT)/mammalian target of rapamycin (mTOR); and iv) programmed death receptor 1 (PD-1). Other hotspots for targeted therapies in the cells of HNSCC are sought after.

EGFR, in other words ErbB1 or Her1 is the most well-known and described cancer drug target. EGFR is a transmembrane protein that belongs to the ErbB/HER family of receptor tyrosine kinases (RTK) activity (12). Extracellular signals, which it transduces, are altered into intracellular responses, influencing cell proliferation, apoptosis, angiogenesis and the capacity of tumor cells to metastasize (12). Following binding the ligand [epidermal growth factor (EGF) or transforming growth factor α (TGFα)], EGFR forms a homodimer or heterodimer with other members of the Erb family (ErbB2, ErbB3 and ErbB4) and activates the downstream signaling through the mitogen-activated protein kinases (MAPKs) cascade and the PI3K/AKT/mTOR pathway (13). This leads to the activation of certain genes in the cell nucleus, which promote angiogenesis, the formation of metastases (13,14). EGFR overexpression can be determined in ~90% of HNSCC (8). It is considered to be a negative prognostic factor that increases the size of the tumor, reduces its radiosensitivity and increases the risk of its recurrence (8). In multivariate analysis, it was demonstrated that EGFR overexpression in patients with stages II–IV HNSCC, treated with standard radiation therapy, was associated with earlier relapse, reduced disease-free survival and overall survival (OS) (13,14). Higher expression of the EGFR receptor is observed in well and moderately differentiated tumors [G1 and G2, according to the Broder's classification (15)], compared with high-grade tumors (G3) (16). Based on meta-analysis of 37 studies by Keren et al (17), EGFR expression was frequent in Austrian, Spanish and Dutch cohorts, in contrast to Swedish, French and Italian populations.

The inhibition of EGFR via targeted therapies is assisted by two types of molecules that differ slightly in the mode of action. The monoclonal anti-EGFR antibody binds to the extracellular domain of EGFR, preventing connections between ligands and thus interferes with the transmission of signals into the cell (18). Destruction of tumor cells is also carried out in the mechanism underlying antibody dependent cellular cytotoxicity (ADCC) (14,18). Whereas the small molecules, EGFR tyrosine kinase inhibitors (TKIs), bind to the cytoplasmic region of EGFR by competing with adenosine-5′-triphosphate, and thereby inhibit the autophosphorylation of EGFR and signal transmission to the lower levels of the intracellular route (14). Further research on the EGFR gene is required. Due to the individual variable response to treatment with targeted therapies, there are various described mutations and polymorphisms of the EGFR gene, which may be a predictive factor for cancer therapy (19).

Cetuximab is a chimeric human immunoglobulin G1 antibody that binds to domain III of the extracellular region of EGFR (12,20). Its effect on tumor cells is based on three different underlying mechanisms, which lead to the induction of apoptosis, inhibition of proliferation, angiogenesis and increase in the response to chemo- and radiotherapy (20). Cetuximab inhibits the phosphorylation of EGFR and transmission of signals to the cell, due to it preventing the attachment of other ligands via its direct binding to the receptor. Furthermore, it induces ADCC, which leads to the removal of coated cells with cetuximab (21). The result of the connection between cetuximab and EGFR may also be the internalization and reduction of the amount of cetuximab on the cell surface (21). The Agency for Food and Drug Administration (FDA) approved the use of cetuximab in cancer therapy in 2004 for the treatment of EGFR-expressing metastatic colon cancer resistant to irinotecan-based chemotherapy (22). After 4 years, in 2006 the FDA approved cetuximab in combination with radiotherapy for the treatment of locally advanced HNSCC on the basis of data were obtained from a multicenter phase III clinical trial (23). It demonstrated a statistically significant improvement in median OS in case of using radiotherapy plus cetuximab in comparison with radiation (49 and 29 months, respectively) in the initially untreated patients with stages III and IV without distant metastases (23).

Vermorken et al (24) demonstrated an increase in median OS by ~3 months and an increase in median progression-free survival (PFS) from 3.3 to 5.6 months in the group with cetuximab and chemotherapy, compared with the group with chemotherapy alone in metastatic or recurrent HNSCC. In 2008, based on the aforementioned trials, Cetuximab was approved by the FDA and European Medicines Agency, for locally advanced or metastatic HNSCC. Despite the improvement in treatment results obtained following the application of cetuximab with radiotherapy in the aforementioned trial, the addition of this monoclonal antibody to chemoradiotherapy based on cisplatin in locally advanced HNSCC did not improve the PFS in stages III and IV HNSCC (25).

An important predictor of locally advanced squamous cell carcinoma of the mouth and throat is human papilloma virus infection (HPV), which is determined by monoclonal antibodies directed against the P16 protein (p16). HPV containing the E7 gene causes the synthesis and increase in the level of p16 in infected cells. HPV positive tumors are characterized by a improved prognosis and a more favorable response to treatment. The NCT00047008 trial obtained 3-year survival in 87% of patients with detected HPV, compared with 57% of patients without such infection (26). There are ongoing phase III trials [Radiation Therapy Oncology Group (RTOG) 1016 and DE-ESCALATE] that compare treatments with cetuximab in combination with intensity modulated radiation therapy (IMRT) and the use of chemoradiotherapy with cisplatin in HPV-positive locally advanced squamous cell carcinoma of the oropharynx (27). It is noteworthy that despite the high EGFR expression in tumor cells of HNSCC, the response rate of cetuximab monotherapy ranges between 10–15% in the treatment of recurrent or metastatic stage of the disease (28). Currently, the only clinical predictor of cetuximab treatment is the severity of skin rash (29). The OS was extended to 68.8 months in patients with rash of grade 2 severity and higher, compared with 25.6 months in patients with rash of grades 0 and 1 severity (30). Therefore, there is a requirement to identify other responses of cancer cells to blocking with EGFR antibodies, as well as to overcome the immunity to such targeted therapies (10,20).

The III variant of EGFR (EGFRvIII) is connected with deletion of 801 base pairs spanning exons 2–7 of the EGFR gene. It may occur in patients with HNSCC and it prevents the operation of cetuximab, as it is devoid of the extracellular domain (27). The clinical implications of the presence of EGFR vIII in HNSCC have not been evaluated in prospective clinical trials.

The trials conducted by RTOG indicate that patients with locally advanced carcinoma may benefit from a combination of cetuximab with docetaxel and concomitant radiotherapy. Another treatment option is the simultaneous administration of cetuximab and PI3K in HNSCC with a mutated PIK3CA gene (31). An indication to overcome the resistance to cetuximab can also be the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitors that disturb MAPK, which are activated in resistant tumor cells (32). The high expression of hepatocyte growth factor (HGF/MET) may serve a role in the resistance to cetuximab (33). Preclinical trials conducted on specific models with the use of HNSCC obtained a reduction of tumor growth following administration of crizotinib, a TKI HGF receptor (HGFR) (33).

Panitumumab is a completely human EGFR monoclonal antibody. It was approved by the FDA in the first-line treatment for patients diagnosed with metastatic colon cancer with the KRAS wild-type. Although, the randomized phase III trial (SPECTRUM) did not indicate any impact of the addition of panitumumab to chemotherapy on the OS of patients with recurrent and metastatic HNSCC, it demonstrated that the addition was associated with increased survival in p16-negative patients (34).

Other human EGFR antibodies include zalutumumab and nimotuzumab. The result of the phase III trial DAHANCA-19 (Danish Head and Neck Cancer Group) did not indicate any significant improvement in local and regional control and overall OS following adding zalutumumab to the radiotherapy (35). Nimotuzumab has a promising effect in patients with advanced HNSCC (36). It is now being assessed in the phase III trial as treatment of locally and regionally advanced nasopharyngeal carcinoma (NCT02012062). The trial compares the effectiveness of nimotuzumab with cisplatin, both drugs are administered to patients during radiotherapy following preoperative chemotherapy according to the TPF (taxotere, cisplatin, 5-fluorouracil) scheme (NCT02012062) (37).

None of the EGFR TKIs has been approved by the FDA for the treatment of HNSCC. These drugs are under review in clinical trials of phase II and phase III (38). Activity of TKIs in the treatment of non-small cell lung cancer is increased by somatic EGFR mutations as exon 19 deletion and the single-point substitution mutation L858R occurring more frequently in females and non-smokers (39). In HNSCC activating mutations are not so frequent but definitely require further study (40).

Gefitinib and erlotinib are the most common TKI, and are useful in the treatment of small cell lung carcinoma. The randomized phase III trial of the Eastern Cooperative Oncology Group demonstrated that the addition of gefitinib to docetaxel did not increase the toxicity of the treatment, but also did not improve the clinical outcome for patients with recurrent and metastatic HNSCC, compared with the use of docetaxel (27). However, it should be noted that patients who were previously heavily-treated or in a poor condition were included in the trial, and this may have had an effect on the data. The phase II trial, that used erlotinib with cisplatin and radiotherapy in the treatment of locally advanced HNSCC, obtained an improved response rate and improvement of the PFS, compared with the group with no antibodies (41).

Lapatinib is a TKI, which has specificity for EGFR (ErbB1). It also inhibits the ErbB2 receptor by the formation of a heterodimer. It is successfully used in the treatment of advanced breast cancer (42). The preliminary trials of it in the treatment of HNSCC have demonstrated its activity in the p-16 negative tumors in combination with chemoradiotherapy (43). A combination of lapatinib and capecitabine can be well-tolerated and active in the metastatic and recurrent forms of HNSCC (44). The ability of lapatinib to inhibit the two receptors can allow a break of the mechanisms underlying resistance to therapy aimed at EGFR antibodies through signal transduction (44).

Afatinib is an irreversible TKI that blocks the transmission of signals from all homo- and heterodimers formed by receptors of the ErbB family. It indicated an anti-proliferative and antitumor activity in pre-clinical cell models (45). It was registered in the first-line treatment of locally advanced or metastatic small cell lung carcinoma in patients with activating mutations in EGFR (46). The phase II trial indicated a comparable clinical efficacy of afatynib to cetuximab in recurrent HNSCC treated previously with chemotherapy based on platinum (47). It is evaluated in the phase III trial as an adjuvant following chemoradiotherapy in the treatment of unresectable advanced (stages III to IVa) HNSCC (48). One of the phase II trials determined that dacomitynib, another EGFR inhibitor, indicated clinical activity in the first-line treatment of recurrent or metastatic HNSCC (49).

VEGF is a signaling protein produced by cells that stimulate angiogenesis (50). It is essential for the organism due to it is responsiblility for the formation of blood vessels during embryonic development, new blood vessels following injuries or a new capillary network that omits obstructed vessels (50). Hypoxia is a factor that induces the expression of VEGF (51). This happens in necrotic and hypoxic regions of tumor tissues (51). Therefore, overexpression of VEGF is present in the majority of HNSCC, consequently favoring tumor growth by changing the microvessel density in the vicinity of cells, cell migration and the formation of distant metastases (51). There is a growing evidence that the reduced sensitivity to radiation and progression of HNSCC is associated with stimulation of angiogenesis by tumor cells that undergo radiotherapy (52). The VEGF family is represented in mammals by five members: VEGF-A, placenta growth factor, VEGF-B, VEGF-C and VEGF-D (52).

There are several strategies aimed at VEGF, which are being evaluated in clinical trials and mediate the inhibition of angiogenesis (52). The most common molecules used in targeted therapies are: Bevacizumab, sorafenib, sunitinib and vandetanib (52). Bevacizumab is a humanized monoclonal antibody that targets VEGF-A. The antitumor therapy uses its ability to inhibit angiogenesis and to increase the delivery of chemotherapeutic agents to tumor cells by reducing microvascular permeability and reducing the pressure inside the tumor (20,52). It is also important that resistance is induced to anti-EGFR agents (20,52). Bevacizumab was approved by the FDA for treatment of advanced cancer types, including colon cancer, kidney cancer, cervical cancer and brain cancer. Preclinical trials reported that bevacizumab has the ability to increase the sensitivity of HNSCC to radiotherapy. The mechanism underlying this phenomenon has not been fully understood. The paradoxical effect of hypoxia is explained by ‘vascular normalization’ (53). Bevacizumab temporarily lead to a decrease in interstitial fluid pressure and improvement in tumor oxygenation (53). Bevacizumab was evaluated in phase I and II clinical trials in combination with erlotinib in patients with recurrent or metastatic HNSCC (54,55).

The results of these trials indicated that this treatment combination increased the complete response rate by ~15% and median survival by 7.1 months (56). There are also trials that demonstrated the benefits of combining pemetrexed with bevacizumab (57). However, the phase II trial, which uses bevacizumab with cetuximab demonstrated no efficacy of this combination in recurrent HNSCC (NCT00409565) (58). The phase II trial, which added bevacizumab to a high dose of cisplatin with IMRT, produced encouraging results of efficacy in the treatment of stage III–IV B HNSCC (59). Researchers are currently waiting for the results of phase II trial on the combination of bevacizumab with chemotherapy, radiotherapy or EGFR inhibitors (NCT00968435) (60).

Sorafenib is a serine-threonine protein kinase inhibitor bRaf, C-Raf, VEGFR and platelet-derived growth factor receptor (PDGFR) (61). It was approved for treatment of advanced kidney cancer, advanced hepatocellular cancer and advanced thyroid cancer resistant to treatment with radioactive iodine (61). It is significant that it induces autophagy, which is a novel prospect of tumor therapy that inhibits tumor growth (61).

Preclinical trials indicated that sorafenib in combination with chemoradiotherapy may increase the antitumor effect by inhibiting cell growth, form cell clones, cell migration and cell invasion, compared with chemoradiotherapy or radiation without sorafenib (62,63). By inhibiting the repair of double-stranded DNA breakages, sorafenib can be used to break the radio-resistance of HNSCC (64). The drug requires evaluation in other clinical trials.

Sunitinib is an oral, small molecule kinase inhibitor that targets VEGFR, PDGFR and c-Kit tyrosine kinase (65). It was approved by FDA for the treatment of renal cancer and imatinib-resistant gastrointestinal stromal tumors (65). Monotherapy with sunitinib demonstrated poor activity in the palliative treatment of HNSCC (65). However, the combination of cetuximab with sunitinib causes a reduction in tumor cell proliferation and an increase in their differentiation (65,66).

Vandetanib is an oral kinase inhibitor targeted on EGFR, VEGFR-2 and the RTK. It was approved by the FDA for the treatment of metastatic medullary thyroid cancer in adult patients who are not candidates for surgery (67). The use of a combination of vandetanib and docetaxel in the treatment of small cell lung carcinoma indicated promising results (67). The use of vandetanib with cisplatin and radiotherapy has the ability to overcome the resistance to EGFR inhibitors in preclinical trials (68). The randomized phase II clinical trial, comparing the treatment of advanced HNSCC in stages III–IV with cisplatin and radiotherapy in combination with or without vandetanib, was prematurely terminated due to an insufficient number of patients to present significant results (NCT00720083) (69). Other VEGF inhibitors that are evaluated in clinical trials for the treatment of HNSCC include: Pazopanib, axitinib, nilotinib and linifanib (70–73).

The PI3K/AKT/mTOR pathway is an intracellular signaling pathway (74). The first signal of this pathway, that is PI3K can be activated in a number of ways. This is conducted by EGFR or insulin-like growth factor 1 receptor and by the adhesion of molecules, including integrins, G protein-coupled receptors (GPCRs) and by oncogenes, including RAS (74). Stimulation of PI3K activates and phosphorylates AKT (74). The active AKT contributes to the downstream effects, including the activation of mTOR. mTOR is a key protein in the pathway (74). The PI3K/AKT/mTOR pathway serves an important role in the regulation of cell cycle, since it promotes the growth and proliferation more than differentiation of adult stem cells (74). Activation of this pathway was detected in numerous tumors and it causes a reduction of apoptosis of cancer cells and an increase of their proliferation (74). mTOR is a serine-threonine kinase. Its function is to regulate the cell cycle, cell survival and proliferation by monitoring the availability of nutrients, cellular energy level, cellular oxygenation and mitogenic signals (75). mTOR operates in two different protein complexes, including CREB-regulated transcription coactivator 1 (TORC1) and TORC2. mTOR is activated in tumors of the head and neck, and is an attractive therapeutic target (76). The expression level of mTOR and lower eukaryotic translation initiation factor 4E (eIF4E), eIF4E-binding protein 1 and ribosomal protein S6 kinase target molecules is a potential diagnostic and prognostic biomarker for tumors of the head and neck (76). There are two types of mTOR inhibitors. The first-generation inhibitors are derived from rapamycin, a macrolide antibiotic that is produced by Streptomyces hygroscopicus bacteria. Rapamycin forms a complex with the cytoplasmic protein peptidyl-prolyl cis-trans isomerase tacrolimus binding protein, which connects to mTOR (77). There are rapamycin analogues, which are used in humans, including temsirolimus and everolimus (77). The second generation mTOR inhibitors are ATP-competitive and include: Torin1, PP242 and PP30 (77). Little is known about them since they have not been evaluated in HNC clinical trials.

Temsirolimus is an intravenous drug that was approved by the FDA for the treatment of kidney cancer (78). The results of several trials performed in vitro on cell lines and in vivo on models of xenograft, demonstrated that temsirolimus inhibits proliferation of HNC (78–80). The trials with cell lines of squamous cell carcinoma of the head and neck indicated that the use of cetuximab in combination with mTOR inhibitors maybe beneficial in the treatment of tumors with high expression of EGFR or acquired resistance to cetuximab. This method of treatment requires further evaluation in clinical trials (81). The phase I clinical trial of temsirolimus and cetuximab in adult patients with advanced or metastatic solid tumors is in progress (NCT02215720) (82). Researchers are currently waiting for the results of phase I/II trial, which used temsiroliums in combination with the weekly administration of chemotherapy with paclitaxel and carboplatin in recurrent or metastatic HNSCC (NCT01016769) (83).

Everolimus is another mTOR inhibitor, which is used as an immunosuppressant to prevent organ transplant rejection and for the treatment of kidney cancer and other cancer types. There are several trials that demonstrated antitumor effect of everolimus for the treatment of HNSCC. Everolimus increased the antitumor effect of docetaxel in the model cell lines and xenografts (84). Currently, everolimus is being evaluated in several clinical trials. The randomized phase II trial compares everolimus to placebo in the adjuvant treatment of patients with locally advanced HNSCC (NCT01111058) (85).

PD-1 is an immunoreceptor and a negative regulator of the immune response (86). It is inducibly expressed on T and B lymphocytes, as well as the on dendritic cells and monocytes. The receptor is activated through binding with one of its ligands: PD-ligand 1 (PD-L1) or PD-L2 (86,87). As a result, the production of cytokines and proteins promoting cell survival diminishes, and synthesis of the interluekin-10 cytokines increases, contributing to the suppression of the inflammatory response (86,87). A prolonged receptor stimulation with an antigen leads to an overexpression of PD-1 on the lymphocytes, which results in to impairment and the exhaustion of function (86,87). The expression of PD-L1 has been proven in cancer cases involving the lungs, colon, stomach, kidneys, breasts, urinary bladder, head and neck and cases of melanoma. It results in a dysfunction of underlying anticancer mechanisms in tumor infiltrating lymphocytes and allows the tumor cells to go unnoticed by immune surveillance (87). The clinical potential of anti-PD-1 and anti-PD-L1 antibodies have been successfully employed in melanoma and lung cancer treatment (88). On August 5, 2016, pembrolizumab was granted accelerated approval by the FDA for patients with recurrent or metastatic HNSCC after platinum-containing chemotherapy. Pembrolizumab was given at 10 mg/kg every two weeks (Group 1) or 200 mg every 3 (Group 2) weeks intravenously. The objective response rate (ORR) and the complete response rates of Groups 1 and 2 were achieved in 16 and 5% of patients, respectively. ORR was observed for six months for >82% (23/28) of responding patients. These data did not depend on HPV status (89). In a phase III trial (NCT02358031), the efficacy of pembrolizumab in monotherapy, combined with standard chemotherapy based on platinum and 5-Fluorouracil for recurrence and/or metastasis HNSCC, compared with the standard forms of treatment. The control group of patients received standard chemotherapy based on platinum and cetuximab (90). At present this trial is ongoing, and its estimated completion date is January 2019.

Nivolumab is another anti-PD-L1 drug approved by FDA in November 2016 for patients with recurrent or metastatic HNSCC and disease progression ≤6 months of receiving the platinum-based chemotherapy (91). The trial enrolled 361 patients randomized to nivolumab 3 mg/kg every 2 weeks intravenously or to investigator's choice of chemotherapy The investigator selected from one of the following drugs: Cetuximab; methotrexate; or docetaxel (92). The trial indicated a statistically significant difference and clinically significant improvement in OS in the nivolumab treatment arm [hazard ratio 0.7 (95% CI: 0.52, 0.92); P=0.0101] (92). Estimated median OS was increased in nivolumab arm, compared with chemotherapy [7.5 months (95% CI=5.5, 9.1) to 5.1 months (95% CI=4, 6.0)] (91,92).

The activin receptor-like kinase-1 (ALK1) is a type I receptor belonging to TGF-β and serves an essential role in modulating angiogenesis and the development of functional vasculature (92–94). Dalantercept (ACE-041) is a novel anti-angiogenic agent, which inhibits ALK1 signaling (94,95). In contrast to other anti-angiogenic agents, ACE-041 does not block the proliferative phase of angiogenesis but it modulates the maturation phase of angiogenesis (94,95).

The phase I study combined with results from preclinical pharmacology studies demonstrated that ACE-041 has a significant potential as an anticancer therapy in patients with advanced solid tumor types, including HNSCC (94,96). The use of ACE-041 in patients with recurrent or metastatic HNSCC requires the results from a phase II clinical trial (NCT01458392) (96). Proteasomes are protein complexes that cause degradation of the proteins responsible for cell growth control. Inhibitors of proteasomes have demonstrated an anticancer activity by the induction of apoptosis and sensitization of malignant cells to conventional cytotoxic drugs (97).

Bortezomib is the first therapeutic proteasome inhibitor to be tested in humans and it is approved by FDA for treatment of relapsed multiple myeloma and mantle cell lymphoma (97). Preliminary results have demonstrated 50% disease control rates in patients with recurrent and metastatic HNSCC and the use of low-dose bortezomib (97). Notably, recent studies demonstrated that the combination of bortezomib with docetaxel, or with cetuximab and radiotherapy, may result in reduced PFS or OS (98,99). GPCRs are the largest family of cell-surface molecules involved in signal transmission and their improved understanding may provide promising opportunities for drug discovery in cancer prevention and treatment (100,101). The Notch signaling pathway is associated with multiple biologic functions, including regulation of self-renewal capacity, differentiation, cell-cycle exit and survival (100,101). The Notch pathway may be a potential therapeutic target in the treatment of different types of cancer (100,101). NOTCH1 mutations have been reported to occur in 10–15% of HNSCC (100,101). Increased activity of Notch has been observed in a number of cancer types (102). Notch inhibition can be conducted by inhibiting four receptors using γ-secretase inhibitors; however, they do not inhibit Notch activation but reduce the activity of further γ-secretase substrates (102). The tumor suppressor role of Notch signaling requires to be evaluated in further studies (102,103).

The discovery of a novel class of cancer medication in the form of biopharmaceuticals led to personalized medicine, which is a novel approach to fighting cancer; however, the heterogeneity of molecular disorders in HNSCC still makes it difficult today to apply optimal, targeted strategies for its treatment. A number of biopharmaceuticals are currently being tested in clinical and preclinical trials; nonetheless, they have not revolutionized HNSCC treatment, and are not the standard treatment option. The identification of molecular markers, which are connected with the response to the treatment used, will help personalize targeted and non-targeted treatment. Ongoing genetic and molecular biology studies may render targeted therapy the fundamental method of cancer treatment in the future.